HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of hepatocellular carcinoma in mice with PE38KDEL type I mutant-loaded poly(lactic-co-glycolic acid) nanoparticles conjugated with humanized SM5-1 F(ab') fragments.

Abstract
We reported previously the development of SMFv-PE38KDEL type I mutant (PE38KDEL-I; Mut-I), a recombinant immunotoxin in which a single-chain antibody derived from mouse SM5-1 monoclonal antibody is genetically fused to PE38KDEL-I. In comparison with the SMFv-PE38KDEL wild-type, Mut-I showed improved therapeutic efficacy and reduced toxicity. To overcome the problems associated with the immune response to the Pseudomonas exotoxin A (PE) component of Mut-I, we have constructed PE38KDEL-I-loaded poly(lactic-co-glycolic acid) nanoparticles conjugated with F(ab') fragments of a humanized SM5-1 monoclonal antibody (PE-NP-S). PE-NP-S specifically bound to SM5-1 binding protein-expressing hepatocellular carcinoma cell lines and was then internalized by these cells, resulting in significant cytotoxic effect. In SM5-1 binding protein-overexpressing tumor xenograft model, administration of PE-NP-S significantly inhibited tumor development and induced tumor regression. Moreover, PE-NP-S was shown to be much weaker in inducing vascular leakage syndrome in mice than Mut-I. The LD(50) of PE-NP-S was about 4-fold higher than that of Mut-I. Remarkably, PE-NP-S was of low immunogenicity in development of anti-PE neutralizing antibodies in vivo and was less susceptible to inactivation by anti-PE neutralizing antibodies compared with Mut-I. In conclusion, the resultant PE-NP-S possessed increased cancer therapeutic efficacy and had reduced nonspecific toxicity and immunogenicity, suggesting that it is a potential candidate in cancer therapy.
AuthorsJie Gao, Geng Kou, Huaiwen Chen, Hao Wang, Bohua Li, Ying Lu, Dapeng Zhang, Shuhui Wang, Sheng Hou, Weizhu Qian, Jianxin Dai, Jian Zhao, Yanqiang Zhong, Yajun Guo
JournalMolecular cancer therapeutics (Mol Cancer Ther) Vol. 7 Issue 10 Pg. 3399-407 (Oct 2008) ISSN: 1535-7163 [Print] United States
PMID18852143 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies
  • Antibodies, Monoclonal
  • Immunoglobulin Fab Fragments
  • Immunotoxins
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Polyglycolic Acid
  • Lactic Acid
Topics
  • Animals
  • Antibodies
  • Antibodies, Monoclonal (therapeutic use)
  • Binding, Competitive (drug effects)
  • Carcinoma, Hepatocellular (drug therapy)
  • Cell Proliferation (drug effects)
  • Endocytosis (drug effects)
  • Humans
  • Immunoglobulin Fab Fragments (therapeutic use, toxicity)
  • Immunotoxins (therapeutic use, toxicity)
  • Lactic Acid (metabolism)
  • Liver Neoplasms (drug therapy)
  • Mice
  • Microscopy, Confocal
  • Nanoparticles
  • Polyglycolic Acid (metabolism)
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: